The 2025 list of the Most Innovative Bio-Manufacturing National Bioindustry Bases was released at the 17th China Bioindustry Convention, held in Wuhan, Hubei Province, on Sept. 6. Photos from Science, Technology and Innovation Bureau of Pingshan District

The Shenzhen State Biological Industry Base in Pingshan District was ranked fourth on the 2025 list of the Most Innovative Bio-Manufacturing National Bioindustry Bases. The list was released at the 17th China Bioindustry Convention, held in Wuhan, Hubei Province, through Sept. 6.

The China Bioindustry Convention is one of the country’s largest and most influential events in biotechnology and the bioindustry. It serves as a major platform to showcase industry development and promote the commercialization of sci-tech achievements, as well as exchanges among biopharmaceutical companies, financial institutions, research organizations, industry associations and government bodies.

The certificate honoring the Shenzhen State Biological Industry Base as one of the Most Innovative Bio-Manufacturing National Bioindustry Bases in 2025.

Approved by the National Development and Reform Commission in June 2005 as one of the first three national bioindustry bases, the Shenzhen State Biological Industry Base covers 3.29 square kilometers of planned area. It focuses on biopharmaceuticals, medical devices and bio-services and is regarded as one of China’s most market-oriented and well-equipped bases for high-tech development and commercialization.

As Shenzhen’s core biopharmaceutical cluster and a catalyst for high-end medical device manufacturing, Pingshan is building a full-chain service system covering R&D, commercialization and production. The district hosts 16 industrial parks in this sector, including the Shenzhen Biomedicine Innovations Industrial Park and the Biomedical Enterprise Accelerator, which together provide more than 2.5 million square meters of high-standard industrial space.

A view of the Shenzhen State Biological Industry Base in Pingshan District.

Pingshan has introduced targeted policies to support biopharmaceutical and innovative drug development, offering strong support for R&D, industrialization and internationalization. The Shenzhen Biopharmaceutical Industry Fund, backed by municipal and district capital, has grown into a 5-billion-yuan fund cluster that provides targeted financial support to innovators.

The district has also launched a rapid drug and medical device approval service mechanism that links municipal, district and park levels. Key platforms for drug and device development and registration have been established to provide one-stop support for faster approvals and market entry.

Pingshan’s bioindustry currently focuses on biopharmaceuticals and high-end medical devices as strategic emerging sectors, with cell and gene industries positioned as future industries. The district is home to 1,290 biopharmaceutical companies, including Fosun Pharma, Sanofi Pasteur, Snibe and Techdow.

In 2024, Pingshan’s biopharmaceutical industry achieved an output value of 26.78 billion yuan; its pharmaceutical sector ranked first in Shenzhen by scale, and its high-end medical device sector ranked second.